Verastem Inc (NASDAQ:VSTM) Director Timothy J. Barberich acquired 30,000 shares of Verastem stock in a transaction dated Monday, May 15th. The shares were bought at an average price of $2.45 per share, for a total transaction of $73,500.00. Following the transaction, the director now owns 69,462 shares of the company’s stock, valued at $170,181.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of Verastem Inc (NASDAQ:VSTM) traded up 3.07% during midday trading on Friday, reaching $2.35. 187,857 shares of the company traded hands. The firm’s market capitalization is $86.93 million. The stock has a 50 day moving average price of $2.03 and a 200 day moving average price of $1.45. Verastem Inc has a 1-year low of $1.05 and a 1-year high of $2.54.
Verastem (NASDAQ:VSTM) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.35). Analysts expect that Verastem Inc will post ($1.31) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/05/19/timothy-j-barberich-purchases-30000-shares-of-verastem-inc-vstm-stock.html.
Several equities research analysts have recently issued reports on the stock. Oppenheimer Holdings Inc. set a $6.00 price objective on shares of Verastem and gave the company a “buy” rating in a research report on Wednesday, May 10th. Cann restated a “buy” rating and issued a $2.00 price target on shares of Verastem in a research report on Thursday, May 11th. Cantor Fitzgerald restated a “hold” rating and issued a $2.00 price target on shares of Verastem in a research report on Thursday, May 11th. Zacks Investment Research cut shares of Verastem from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, CIBC restated an “outperform” rating and issued a $6.00 price target on shares of Verastem in a research report on Thursday, April 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $3.64.
Several hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC increased its stake in shares of Verastem by 20.0% in the first quarter. Renaissance Technologies LLC now owns 1,226,600 shares of the biopharmaceutical company’s stock worth $2,539,000 after buying an additional 204,400 shares during the period. Geode Capital Management LLC boosted its position in Verastem by 0.4% in the first quarter. Geode Capital Management LLC now owns 188,743 shares of the biopharmaceutical company’s stock worth $390,000 after buying an additional 750 shares in the last quarter. Vanguard Group Inc. boosted its position in Verastem by 5.2% in the first quarter. Vanguard Group Inc. now owns 1,036,613 shares of the biopharmaceutical company’s stock worth $2,145,000 after buying an additional 51,306 shares in the last quarter. TFS Capital LLC acquired a new position in Verastem during the first quarter worth $113,000. Finally, FMR LLC boosted its position in Verastem by 32.2% in the fourth quarter. FMR LLC now owns 901,200 shares of the biopharmaceutical company’s stock worth $1,009,000 after buying an additional 219,445 shares in the last quarter.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem Inc and related companies with MarketBeat.com's FREE daily email newsletter.